Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.7179 +0.0152 (+2.16%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
33 34 Next >
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Odonate Therapeutics, Inc. (NASDAQ: ODT) shares rose 38.3% to $4.80 in pre-market trading following 13G from Ikarian Capital showing a 5.2% stake in the company. BSQUARE... 
Via Benzinga
Don’t Play the Ocugen Stock Short Squeeze Before You Read This Warning!
Growing trends involving OCGN stock suggest that the bears may have the upper hand this time. 
Via InvestorPlace
Exposures COVID-19
Ocugen Has Had a Good Run, but the Math Says It’s Over
Ocugen was a penny stock is up 180% for the year. But all good things must come to an end. And it’s time to let go of OCGN stock. 
Via InvestorPlace
Exposures COVID-19
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
3 Tips for Coronavirus Investing Right Now
Whether you're a cautious or aggressive investor, there's something for you in this space. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
One Bright Spot for Ocugen Investors
It may equal some coronavirus vaccine revenue ahead. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Odonate Therapeutics (NASDAQ:ODT)... 
Via Benzinga
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Opportunity for Investors With Substantial Losses to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
How Risky Is Ocugen After Its Recent Setback?
The U.S. vaccine market has slipped farther out of reach. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Better Short-Squeeze Stock: Clover Health or Ocugen?
Both have the necessary ingredients for explosive short-squeeze returns. 
Via The Motley Fool
Why Ocugen Shares Are Slipping Today
It could be due to the aftereffects of being included in a major stock index. 
Via The Motley Fool
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Sell Ocugen Stock Before the Other Shoe Finally Drops
The bad news with Covaxin hasn't sunk in yet with OCGN stock investors, so get out while the stock still remains elevated. 
Via InvestorPlace
Exposures COVID-19
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
What's Going On With Ocugen (OCGN) Stock Today?
Ocugen Inc (NASDAQ: OCGN) shares are trading 1.6% higher in the pre-market session on Wednesday amid high social media interest. The company's shares had closed nearly 2%... 
Via Benzinga
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN
From The Rosen Law Firm, P.A.
Via Business Wire
NASDAQ:OCGN Shareholder Alert: Lawsuit Alleges Securities Laws Violations by Ocugen, Inc.
San Diego, CA -- (SBWIRE) -- 06/29/2021 -- An investor, who purchased NASDAQ:OCGN shares, filed a lawsuit against Ocugen, Inc. over alleged violations of Federal Securities Laws. 
Via SBWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
If Ocugen Stock Is Worth $8, I’ll Eat My Hat
OCGN stock at $8.35 looks ridiculously overvalued given the change in course 
Via InvestorPlace
Exposures COVID-19
OCGN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Ocugen, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Ocugen Stock Is A Bust After Covaxin’s Emergency Use Rejection
OCGN stock is of no value to investors now that federal regulators closed the door on its Covid-19 vaccine commercialization efforts. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Is It Too Late to Buy Ocugen Stock?
The company has found a partner to manufacture its COVID-19 vaccine -- but will it be all for naught? 
Via The Motley Fool
Exposures COVID-19
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Get Rid of Ocugen Stock While You Can as the Bad News Piles Up
After OCGN stock rallied due to factors that were not based on fundamentals, investors should sell the shares. 
Via InvestorPlace
Exposures COVID-19
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Why Ocugen Climbed 8% Higher Today
The company will join a rarefied club starting early next week. 
Via The Motley Fool
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
From Law Offices of Howard G. Smith
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.